Prelude Capital Management, LLC Nektar Therapeutics Transaction History

Prelude Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $23,733 - $28,640	-1,505 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$16.59 - $24.79 $109,046 - $162,944	-6,573 Reduced 81.37%	1,505 $25,000
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $136,195 - $189,348	8,078 New	8,078 $187,000
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $209,901 - $405,587	-14,506 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $230,210 - $335,378	14,506 New	14,506 $313,000
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $11,319 - $21,073	-372 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $17,283 - $25,478	372 New	372 $23,000
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $112,711 - $254,544	-2,437 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $134,316 - $253,749	2,340 Added 2412.37%	2,437 $259,000
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $379,599 - $997,645	-16,490 Reduced 99.42%	97 $6,000
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $295,082 - $398,088	16,587	16,587 $398,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $247M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.